Neuroendokrines Prostatakarzinom

Autor:	R Erdelkamp, M Hentrich, S Tritschler, C Stief
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology medicine.medical_specialty Urology medicine.medical_treatment urologic and male genital diseases Pathology and Forensic Medicine Androgen deprivation therapy 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Prostate Internal medicine medicine Etoposide Chemotherapy biology business.industry Obstetrics and Gynecology Chromogranin A medicine.disease Carboplatin 030104 developmental biology medicine.anatomical_structure Docetaxel chemistry 030220 oncology & carcinogenesis biology.protein business medicine.drug
Zdroj:	Der Pathologe. 39:333-343
ISSN:	1432-1963 0172-8113
DOI:	10.1007/s00292-018-0453-7
Popis:	Neuroendocrine prostate cancer (NEPC) mostly occurs as a treatment-emergent adaptive response under the pressure of intensive androgen deprivation treatment (t-NEPC). Approximately 30-40% of patients with metastatic castration-resistant prostate cancer (mCRPC) also have neuroendocrine involvement. In contrast primary small cell prostate cancer is very rare (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::226b0609ce61d1af1bbba6c96eb6e858 https://doi.org/10.1007/s00292-018-0453-7 Zobrazit plný text záznamu Full text from SpringerLink